Fri, Jan 30, 2015, 2:29 AM EST - U.S. Markets open in 7 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Shire plc Message Board

quikquikslow 4 posts  |  Last Activity: Dec 29, 2014 11:53 PM Member since: Nov 13, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • quikquikslow quikquikslow Dec 29, 2014 11:53 PM Flag

    I'm pretty sure that BCEL only held PLX shares in 2014. BCEL still trades on the TASE and has a market cap of $891,423 USD. So, I would assume that they still hold shares. I've been waiting for BCEL to sell all of their shares.

  • quikquikslow quikquikslow Dec 29, 2014 5:17 PM Flag

    dfkerem:

    Do you know the status of BCEL's stake in PLX? Does it still have shares?

  • quikquikslow quikquikslow Nov 15, 2014 1:17 AM Flag

    Findings
    Between April 18, 2012, and Dec 14, 2012, 109 participants were randomly assigned to PBT2 250 mg (n=36), PBT2 100 mg (n=38), or placebo (n=35) at 19 research centres in Australia and the USA. 32 (89%) individuals on PBT2 250 mg, 38 (100%) on PBT2 100 mg, and 34 (97%) on placebo completed the study. Six serious adverse events (acute coronary syndrome, major depression, pneumonia, suicide attempt, viral infection, and worsening of Huntington's disease) occurred in five participants in the PBT2 250 mg group, three (fall with subdural haematoma, suicide attempt, and hospital admission for stabilisation of Huntington's disease) occurred in two participants in the PBT2 100 mg group, and one (increasing aggression) occurred in a participant in the placebo group. The site investigators deemed all, except the worsening of Huntington's disease, as unrelated to study drug. 32 (89%) participants on PBT2 250 mg, 30 (79%) on PBT2 100 mg, and 28 (80%) on placebo had at least one adverse event. Compared with placebo, neither PBT2 100 mg (least-squares mean 0·02, 95% CI −0·10 to 0·14; p=0·772) nor PBT2 250 mg (0·07, −0·05 to 0·20; p=0·240) significantly improved the main composite cognition Z score between baseline and 26 weeks. Compared with placebo, the Trail Making Test Part B score was improved between baseline and 26 weeks in the PBT2 250 mg group (17·65 s, 0·65—34·65; p=0·042) but not in the 100 mg group (0·79 s improvement, −15·75 to 17·32; p=0·925); neither dose significantly improved cognition on the other tests.

  • Don't know what Brewman is talking about.

SHPG
222.17+2.72(+1.24%)Jan 29 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.